TAKEDA PHARMACEUTICAL CO LTD

Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in research, development, and commercialization of prescription therapeutics. The organization centers its commercial operations around six primary areas: gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. Its diversified product lineup includes key offerings such as Entyvio, Gattex, Takhzyro, Gammagard Liquid, Hyqvia, Adcetris, Vyvanse, and the Qdenga vaccine. Serving patients across the globe suffering from both widespread conditions and rare disorders, the business develops treatments spanning biologics, small molecules, and plasma extractions.

The enterprise maintains an international operating footprint across approximately 80 countries and regions, employing around 47,000 individuals. Its commercial operations maintain a significant presence in the United States, Japan, and Europe, alongside growing activities in China. Its worldwide infrastructure incorporates manufacturing locations, over 270 plasma donation centers in the United States and Europe, and major research facilities in Japan, the United States, and Austria. The global corporate headquarters is situated in Tokyo, Japan.

Summary of the business section of Takeda Pharmaceutical's latest annual report, written by StockData.

“We have approximatel y 47,000 employees worldwide, and our culture is based on our values of Takeda-ism which incorporates Integrity, Fairness, Honesty, and Perseverance, with Integrity at the core.”